

Supplementary digital content 2

Table S1. Summary of PK Parameters for Stage 1 Participants Enrolled in Stage 2—Week 2 Results for Stage 2 Doses (Final Doses Selected in Stage 1) (Study A4001031)

Analysis Set	Median Weight (Range), kg	Median BSA (Range), m ²	Geometric Mean C _{avg} (Range), ng/mL	Geometric Mean C _{max} (Range), ng/mL	Geometric Mean AUC _{tau} (Range), ng-hr/mL
Overall					
Total (N=50)	26.8 (10.0-57.6)	1.0 (0.5-1.6)	248.5 (72.0-843.6)	527.0 (174.0-1870.0)	2981.6 (864.0-10123.0)
Potent inhibitor OBT (n=38)	24.4 (10.0-57.6)	0.9 (0.5-1.6)	267.3 (102.5-843.6)	504.4 (176.0-1180.0)	3207.9 (1230.0-10123.0)
Neutral OBT (n=10)	32.1 (16.2-40.3)	1.1 (0.7-1.3)	186.3 (72.0-318.7)	517.7 (174.0-1110.0)	2235.7 (864.0-3825.0)
Potent inducer OBT (n=2)	32.8 (17.0-48.5)	1.1 (0.7-1.4)	261.1 (168.5-404.4)	1325.8 (940.0-1870.0)	3132.7 (2022.0-4852.0)
Cohort 1: ≥2 to <6 years of age, maraviroc oral solution					
Total (n=12)	16.0 (10.0-17.6)	0.7 (0.5-0.7)	237.3 (113.6-843.6)	581.5 (205.0-1870.0)	2848.1 (1363.0-10123.0)
Potent inhibitor OBT (n=9)	14.3 (10.0-17.1)	0.6 (0.5-0.7)	243.6 (113.6-843.6)	483.1 (205.0-1180.0)	2923.1 (1363.0-10123.0)
Neutral OBT (n=2)	16.9 (16.2-17.6)	0.7 (0.7-0.7)	161.8 (114.3-229.0)	746.5 (502.0-1110.0)	1941.3 (1371.0-2748.0)
Potent inducer OBT (n=1)	17.0 (N/A)	0.7 (N/A)	404.4 (N/A)	1870.0 (N/A)	4852.4 (N/A)
Cohort 2: ≥6 to <12 years of age, maraviroc tablet formulation					
Total (n=11)	27.6 (21.7-39.2)	1.0 (0.9-1.3)	260.7 (120.0-401.7)	546.8 (232.0-905.0)	3127.7 (1440.0-4820.0)
Potent inhibitor OBT (n=9)	27.6 (21.7-39.2)	1.0 (0.9-1.3)	274.7 (120.0-401.7)	543.6 (232.0-905.0)	3296.5 (1440.0-4820.0)
Neutral OBT (n=2)	32.4 (27.6-37.2)	1.1 (1.0-1.2)	205.8 (166.5-254.2)	561.6 (360.0-876.0)	2468.9 (1998.0-3051.0)
Potent inducer OBT (n=0)	N/A	N/A	N/A	N/A	N/A
Cohort 3: ≥6 to <12 years of age, maraviroc oral solution					
Total (n=10)	22.2 (13.9-57.6)	0.9 (0.6-1.6)	264.5 (102.5-613.2)	444.4 (176.0-995.0)	3173.4 (1230.0-7358.0)
Potent inhibitor OBT (n=9)	22.9 (13.9-57.6)	0.9 (0.6-1.6)	282.3 (102.5-613.2)	459.6 (176.0-995.0)	3387.5 (1230.0-7358.0)
Neutral OBT (n=1)	21.4 (N/A)	0.8 (N/A)	146.9 (N/A)	328.0 (N/A)	1763.1 (N/A)
Potent inducer OBT (n=0)	N/A	N/A	N/A	N/A	N/A
Cohort 4: ≥12 to <18 years of age, maraviroc tablet formulation					
Total (n=17)	37.5 (24.0-52.3)	1.2 (0.9-1.6)	239.9 (72.0-613.0)	530.8 (174.0-1050.0)	2878.2 (864.0-7356.0)
Potent inhibitor OBT (n=11)	42.0 (24.0-52.3)	1.3 (0.9-1.6)	269.8 (111.0-613.0)	530.4 (188.0-1050.0)	3237.6 (1332.0-7356.0)
Neutral OBT (n=5)	35.0 (31.1-40.3)	1.2 (1.1-1.3)	198.7 (72.0-318.7)	474.3 (174.0-721.0)	2384.1 (864.0-3825.0)
Potent inducer OBT (n=1)	48.5 (N/A)	1.4 (N/A)	168.5 (N/A)	940.0 (N/A)	2022.5 (N/A)

AUC, area under the curve; BSA, body surface area; C_{avg}, average concentration; C_{max}, maximum concentration; N, number of participants in cohort;

n, number of participants with observations; N/A, not applicable; OBT, optimized background therapy; PK, pharmacokinetic.